LADENBURG THALM/SH SH Downgrades Bionano Genomics (NASDAQ:BNGO) to Neutral

Bionano Genomics (NASDAQ:BNGO) was downgraded by equities research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research note issued on Friday, Marketbeat Ratings reports.

Other analysts also recently issued research reports about the company. BTIG Research downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th. Scotiabank reaffirmed a “sector perform” rating and set a $1.00 price target (down previously from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th.

Bionano Genomics Trading Down 3.8 %

BNGO opened at $0.25 on Friday. Bionano Genomics has a twelve month low of $0.24 and a twelve month high of $2.27. The firm has a market cap of $21.16 million, a PE ratio of -0.05 and a beta of 2.37. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.11 and a current ratio of 1.63. The firm’s fifty day moving average is $0.36 and its two-hundred day moving average is $0.60.

Institutional Investors Weigh In On Bionano Genomics

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Bionano Genomics in the 1st quarter worth $36,000. Carret Asset Management LLC boosted its position in shares of Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Bionano Genomics during the third quarter worth about $46,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after buying an additional 38,900 shares in the last quarter. Finally, Cetera Advisors LLC acquired a new stake in Bionano Genomics in the 1st quarter valued at approximately $163,000. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.